MOLBIO

- Trading window for dealing in company securities will remain closed from October 01, 2026. - Closure will continue until 48 hours after declaration of unaudited financial results for the quarter ended September 30, 2026. - Date of the Board Meeting will be intimated in due course.

- Molbio Diagnostics Limited re-appointed M/s K. S. Kamalakara & Co., Cost Accountants, as the Cost Auditor of the Company for the financial year 2026-27. - The board meeting for the re-appointment was held on September 25, 2026.

- Concall Schedule - Concall Date: September 22, 2026 - Concall Time: 11.00 A.M. (IST)

- Q1 FY27 Consolidated Revenue from operations stood at ₹408 crores. - EBITDA for Q1 FY27 was ₹104 crores, representing a 25% margin, and Profit After Tax (PAT) was ₹52.7 crores (13% of revenue). - Export revenue for the quarter was ₹67 crores (16% of total revenue), including a catch-up from Q4 FY26. - FY27 annual guidance projects ~25% top-line growth and 24-25% EBITDA margin. - R&D investment is expected to be 5-6% of revenue, focusing on new platforms and non-communicable diseases. - Capex includes ₹72 crores for automation and ₹105 crores for an integrated R&D center, funded by IPO proceeds. - OptraScan is not expected to be profitable in FY27 but is anticipated to contribute meaningfully from FY28-29. - Truenat HPV test received Indian government validation for national program rollout; OptraScan received US FDA clearance for its entire workflow. - Secured a two-year rate contract for TB testing with the Government of India.

- Intimation of change in Corporate Identification Number (CIN) for Molbio Diagnostics Limited. - New CIN: L33125GA2000PLC002909 (previously U33125GA2000PLC002909). - Status on MCA portal changed from 'Unlisted' to 'Listed' post-listing on NSE and BSE on August 17, 2026.

- Molbio Diagnostics Limited announced the availability of the audio recording of the Earnings Call for the quarter ended June 30, 2026. The call was held on September 08, 2026, and the recording is available on the company's website.

- Q1 FY27 Consolidated Total Income ₹411.48Cr - EBITDA ₹103.68Cr in Q1 FY27 vs loss of ₹14.50Cr in Q1 FY26 (turned from loss to profit YoY) - EBITDA Margin 25.19% in Q1 FY27

- Q1 FY27 Consolidated Total Income ₹411.48 Cr vs ₹100.47 Cr (▲309.6% YoY) - EBITDA ₹103.68 Cr vs (₹14.50) Cr (swung from a loss of ₹14.50 Cr to a profit of ₹103.68 Cr YoY) - PAT ₹52.74 Cr vs (₹23.94) Cr (swung from a loss of ₹23.94 Cr to a profit of ₹52.74 Cr YoY) - EBITDA Margin 25.20% vs (14.43%) (▲3963bps)

- Concall Schedule - Concall Date: Tuesday, 08th September 2026 - Concall Time: 04:00 PM IST

- Board meeting held on August 27, 2026. - Mr. Darshan Raghunath Karekar was designated as the Compliance Officer under SEBI (PIT) Regulations, 2015, formalizing his existing role as Compliance Officer.

- Molbio Diagnostics Ltd. has intimated the closure of the trading window for insiders as per SEBI PIT Regulations. - The trading window will be closed from August 21, 2026. - It will remain closed until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. - The date of the Board Meeting for the said results will be intimated in due course.